BeOne Medicines Q3 Adjusted Earnings, Revenue Rise; 2026 Revenue Guidance Raised -- Shares Up Pre-Bell

06:23 AM EST, 11/05/2026 (MT Newswires) -- BeOne Medicines (ONC) reported Q3 adjusted earnings Thursday of $4.59 per diluted American depositary share, up from $2.65 a year earlier. Two analysts polled by FactSet expected $2.82. Revenue for the quarter ended Sept. 30 was $1.89 billion, compared with $1.41 billion a year earlier. Analysts expected $1.75 billion. BeOne said it now expects 2026 total revenue of $6.9 billion to $7.0 billion, up from its prior outlook of $6.6 billion to $6.8 billion. Analysts polled by FactSet expect $6.78 billion. Shares of the company were up 5.9% in premarket activity.